Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. Kang (Seoul, Republic of Korea). Cardiovascular disease risk in patients with nontuberculous mycobacteria disease treated with macrolide. 1974

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary nontuberculous mycobacerial disease in elderly patients Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Outcomes of patients undergoing treatment for non-tuberculous mycobacteria lung disease Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019 Management of pulmonary nontuberculous mycobacteria disease Source: Eur Respir Monogr 2018; 81: 222-237 Year: 2018 When is an infectious disease? The clinical spectrum of nontuberculous mycobacterial pulmonary disease Source: International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Year: 2019 Risk of nontuberculous mycobacterial pulmonary disease with obstructive lung disease Source: Eur Respir J 2016; 48: 928-931 Year: 2016 Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients Source: Eur Respir J 2006; 28: 1211-1215 Year: 2006 Surgery in nontuberculous mycobacteria pulmonary disease Source: Breathe, 14 (4) 288; 10.1183/20734735.027218 Year: 2018 The impact of new ATS/IDSA guideline for nontuberculous mycobacterial disease on the diagnosis of nontuberculous mycobacterial lung disease in Korea Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008 Cure rates in nontuberculous mycobacterial pulmonary disease Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Patient reported outcomes for non-tuberculous mycobacterial disease Source: Eur Respir J, 55 (1) 1902204; 10.1183/13993003.02204-2019 Year: 2020 New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Source: Virtual Congress 2020 – German programme 2020 Year: 2020 Cases series on nontuberculous mycobacterial (NTM) lung disease and silicosis in Brazil Source: International Congress 2017 – Case reports and series Year: 2017 Perspectives on antibiotic treatment of NTM pulmonary disease Source: Eur Respir Monogr 2017; 75: 245-252 Year: 2017 Non-tuberculous mycobacterial lung disease and COPD Source: Eur Respir Monogr 2015; 69: 172-184 Year: 2015 Risk factors for fatal tuberculosis among immunocompetent patients. Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response Source: Eur Respir J 2004; 23: 741-746 Year: 2004 Prevalence, risk factors and prognosis of nontuberculous mycobacterial infection among people with bronchiectasis: a population survey Source: Eur Respir J, 51 (5) 1702469; 10.1183/13993003.02469-2017 Year: 2018 Evaluation of tuberculosis risk in patients submitted to chronic immunosuppressive therapy for osteoarticular immune disease Source: Eur Respir J 2006; 28: Suppl. 50, 131s Year: 2006